Abstracts significantly more likely to experience an ER visit or an inpatient stay compared to patients in capitated plans (odds ratio for ER visit: 1.64, p < 0.05; odds ratio for an inpatient stay: 1.11, p < 0.05). CONCLUSIONS: The results of this study confirm that utilization rates are higher in FFS plans; however, the strength of the association was not as robust when the regression models were adjusted for propensity score. Capitated plans seek to reduce resource utilization.
PDB64 USING DECISION MODELING TO DETERMINE COST-EFFECTIVENESS OF PHARMACIST INTERVENTIONS FOR PATIENTS WITH DIABETES
Pinto S, Holl S University of Toledo, Toledo, OH, USA OBJECTIVES: Prevention or mediation of adverse events can significantly impact a patient's quality of life and their employer's health care costs. Decision modeling can be utilized to map pharmacists interventions provided through an employee-sponsored medication therapy management (MTM) program and calculate consequent cost savings associated with improved clinical outcomes. METHODS: A total of 700 employees from 2 employer groups participate in a pharmacist provided MTM program. A team of clinicians and researchers classified and created codes for specific pharmacist interventions, resultant physician and/or patient responses, and consequent outcomes. Data was extracted from patient charts and entered into Microsoft Excel. Costs associated with each decision outcome were calculated from claims data. A one-year decision-analytic model was constructed using TreeAge Pro Suite 2008 to identify the cost savings per intervention. RESULTS: A total of 218 interventions were made by the pharmacists. The most frequently used interventions were "explained and advised the use of pattern management" (N = 95, 43.4%) and "alerted the physician of an abnormal A1c level" (N = 64, 29.2%). Cost savings resulting from diabetic interventions for ER visits ($71.00 -$337 PPPY), inpatient hospitalization ($460.00 -$2360.00 PPPY), and total costs ($26.00 -$274.00 PPPY). All but one intervention resulted in a loss of cost savings for office visits, indicating that patients visited specialty physicians more often after beginning the program. The total cost savings for these interventions were $165.00 PPPY and $145.00 PPPY, respectively. CONCLU-SIONS: This decision-analytic model can be used as a rubric for providers seeking the most effective interventions to utilize for MTM programs, thereby reducing trial-anderror and diminishing health care costs. The model illustrates the potential return on investment the employer realized as a result of sponsoring employee participation in this program.
PDB65 IMPROVED PATIENT OUTCOMES RESULTING FROM PHYSICIANS' THERAPY DECISIONS BASED ON PHARMACISTS' RECOMMENDATIONS
Pinto S, Blazejewski L, Holl S University of Toledo, Toledo, OH, USA OBJECTIVES: Literature suggests that while pharmacists may be viewed as the most trusted health care professionals by patients, other health care professionals may often fail to trust them with making decisions regarding drug therapy regimens. Limited information is available regarding physicians' therapy decisions based on pharmacist's recommendations and the resulting patient clinical outcomes. This study aimed at finding if physicians' therapy decisions based on pharmacist's recommendations lead to optimal patient outcomes. METHODS: Approximately 700 employees from 2 employer groups have participated in an employer-supported pharmacist provided disease state management program. The program is provided at seven independent pharmacies across Northwest Ohio. A team of clinical pharmacists and researchers classified and created codes for specific pharmacist-provided interventions, resultant physician and/or patient responses, and consequent outcomes. Data was extracted from patient charts and entered into Microsoft Excel. Frequencies and percentages of pharmacists' interventions, physicians' responses and outcomes were calculated using SPSS ver. 17.0. A decision tree was created using TreeAge Pro Suite 2008 to map interventions to responses to improved/unimproved outcomes. RESULTS: A total of 446 pharmacist interventions with corresponding physician responses and patient outcomes were made. The most frequent interventions involved drug therapy (N = 138, 31%) and formulary management (N = 105, 23.5%). The most frequent responses by physicians were "physician acknowledged recommendation, monitoring added" (N = 58, 13%) and "physician added a medication" (N = 51, 11.4%). Physicians responded favorably to the pharmacists' interventions 54.1% of the time. When physicians responded favorably, an improvement was seen in 91.2% of patient outcomes compared to only 64% when physicians declined or did not respond to pharmacists' interventions. CONCLUSIONS: Positive health outcomes result from therapy decisions made by physicians following pharmacists' recommendations. In an effort to save costs and improve care, pharmacist-physician collaboration is essential. were used in the RADAR tool to assess the yearly rate of glycosylated hemoglobin (HbA1c) testing and low-density lipoprotein-cholesterol (LDL-C) screening. Other HEDIS comprehensive diabetes care-related measures reported by the RADAR tool included the rate of patients with (a) hypertension; (b) nephropathy; and (c) retinopathy. Variables such as demographic, clinical, pharmacy, and medical utilization patterns along with medication adherence were also reported. RESULTS: A total of 287,195 patients with diabetes were identified, with 92% of the patients identified as having type 2 diabetes. Mean age of the patients was 53 years, and 52% were male. Over 70% of the patients with diabetes had cardiovascular risk factors such as hypertension; 4%, 13%, and 11% of the diabetes population had nephropathy, neuropathy, and retinopathy, respectively. Sixty-seven percent of the diabetes patients received HbA1c testing, while 71% of the patients received LDL-C screening within one year. Testing within one year was less than the national HEDIS Medicaid 25th percentile level (74.4%) for HbA1c and greater for LDL-C screening (66.9%). The RADAR tool effectively evaluated the selected HEDIS comprehensive diabetes care measures in the i3 Innovus database. CONCLUSIONS: In this population, LDL-C screenings within one year for diabetes patients were above the national HEDIS lowperformance level, while HbA1c testing within one year for diabetes patients was below the low-performance level, utilizing the RADAR tool for analyses. These findings indicate an opportunity for improvement.
PDB66 EVALUATION OF SELECTED COMPREHENSIVE DIABETES CARE

PDB67 ECONOMIC EVALUATION OF TYPE 2 DIABETES -IMPACT OF PRICING AND REIMBURSEMENT REFORMS
Ilavska A 1 , Glatz P 2 , Hloska A 3 , Filko M 4 1 Medispektrum, Bratislava, Slovak Republic, 2 Janssen-Cilag, Bratislava, Slovak Republic, 3 Ministry of Health, Bratislava, Slovak Republic, 4 Ministry of Finance, Bratislava, Slovak Republic OBJECTIVES: Type 2 diabetes mellitus is serious condition associated of chronic complications whose economic impact on both patients and society is constantly increasing. Diabetics are the 4st in the drug spending in Slovakia. Our objectives was to explore drug costs for diabetes and besides the costs to explore also drug consumption and number treated patients with antidiabetics. METHODS: The data on drugs consumption were from national databases IMS Health and Pharmadata Ltd. 
PDB69 OLDER PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES (T2DM) EXPERIENCE MORE DELAYED TREATMENT WITH ORAL ANTIHYPERGLYCEMIC AGENTS COMPARED WITH YOUNGER PATIENTS
Zhang Q 1 , Rajagopalan S 2 , Marrett E 1 , Radican L 1 1 Merck, Whitehouse Station, NJ, USA, 2 MedData Analytics, Inc., Williamsville, NY, USA OBJECTIVES: This study compared older (≥ 65 yrs) and younger patients with newly diagnosed T2DM, and evaluated factors associated with oral antihyperglycemic agent (OAHA) initiation. METHODS: This retrospective cohort study used U.S. General Electric (GE) Centricity electronic medical record database. Patients aged ≥30 yrs with newly-diagnosed T2DM (January-2003 to December-2005) were included. There was no diabetes diagnosis or treatment within 2 years prior to the first recorded T2DM diagnosis. Medical records 1 year prior to (baseline) and 2 years after (follow-up) diagnosis were extracted. OAHA initiation was estimated based on the first OAHA prescription during follow-up. Multivariable Cox proportional hazards regression model was fitted. Untreated patients were censored at complete 2 years follow-up. RESULTS: Among 10,760 newly diagnosed T2DM patients, 55% were female. Mean age at T2DM diagnosis was 61.3( ± 12.5), with 4,617 (43%) ≥65 yrs. At baseline, older relative to younger patients had lower HbA1c (6.7% vs. 7.2%, with only 38% vs. 32% attaining HbA1c < 7% goal), lower fasting blood glucose (117.9 vs. 132.8 mg/ dL) and lower BMI (30.6 vs. 35.2), higher rates of acute myocardial infarction (MI) (2.1% vs. 0.9%), heart failure (5.1% vs. 1.8%), stroke (3.1% vs. 0.8%), and renal disease (17.5% vs. 6.2%), and more co-medications (all p-values < 0.05). Within 2 years after T2DM diagnosis, 56% older and 40.5% younger patients (P < 0.001) had not received OAHA. Older patients were less likely to be treated than younger patients (adjusted hazard ratio 0.84, p < 0.001). Additionally, patients with baseline MI or renal disease were less likely to be treated (p < 0.05). Higher BMI or HbA1c at baseline, and heart failure, initiating antihypertensive or lipid lowering drugs after T2DM diagnosis were factors associated with increased likelihood of OAHA treatment (p < 0.05). CONCLUSIONS: Older patients with newly diagnosed T2DM had milder hyperglycemia but more comorbidities, and experienced more delayed OAHA therapy than younger patients.
PDB70 EVALUATION OF SITAGLIPTIN DOSING AMONG RENAL IMPAIRED TYPE 2 DIABETES MELLITUS PATIENTS
Krishnarajah G, Dezii C, Tran M, Balar BA Bristol Myers Squibb, Plainsboro, NJ, USA OBJECTIVES: To evaluate the dosing of sitagliptin for type 2 diabetes mellitus (T2DM) patients with renal impairment. METHODS: This was a retrospective crosssectional analysis using the General Electric Electronic Medical Records. The study population (N = 1539) was patients with T2DM and renal impairment (defined using ICD-9-CM codes) who were prescribed sitagliptin between April 1, 2006 and June 30, 2008 . Based on the label, 100mg of sitagliptin is the recommended dose for patients with normal or mild renal impairment (CrCl≥50), 50mg for patients with moderate renal impairment (50 > CrCl≥30), and 25mg for severe or end-stage renal disease (ESRD)(30 > CrCl). Baseline severity of renal impairment was determined using calculated GFR values using the 4-point Modification of Dosing in Renal Disease (MDRD) formula. Patients with GFR level ≥60 were considered normal to mild cases, 30 to < 60 were moderate cases, 15 to <30 were severe cases, and <15 or patients on dialysis had ESRD. Univariate analysis was done on age, gender, race, US region, payment source, comorbidities and Charlson-comorbidity index to identify factors that may be associated with inappropriate dosing. RESULTS: Of the 1,539 renally impaired patients with T2DM who received sitagliptin, 804(52%) had moderate renal impairment and 158(11%) had severe renal impairment or ESRD. Two-thirds of all moderate to severe and ESRD renally impaired patients had initial sitagliptin prescriptions that were higher-than-recommended doses. At 12-month follow-up, 87% of patients, whose initial prescription was for a higher-than-recommended-dose of sitagliptin, continued to be on the inappropriate higher dose. Univariate analysis showed there were no significant differences in dosing by age, gender, race, US region, insurance type or comorbidities. CONCLUSIONS: Indiscriminant of patient characteristics, 2/3's of the population of sitagliptin users recommended a lower dose due to renal impairment, were found to be inappropriately dosed higher-than-recommended. This inappropriate dosing was not corrected during a year-long follow-up.
PDB72 POTENTIALLY PREVENTABLE HOSPITALIZATIONS FOR DIABETES COMPLICATIONS, CARE ORGANIZATION AND CONTINUITY OF CARE
Modi A 1 , Carney Doebbeling C 2 , Thomas III J 1 1 Purdue University, West Lafayette, IN, USA, 2 Office of Medicaid Policy and Planning, Indianapolis, IN, USA OBJECTIVES: Understanding affects of care organization and continuity of care on potentially preventable hospitalizations for diabetes complications (DC) is important for policy development and outcomes management. We determined DC rates among Medicaid beneficiaries and assessed associations between care organization and DC. METHODS: A retrospective cohort analysis of Indiana Medicaid claims, enrollment, and encounter data was conducted. Sample inclusion criteria were ≥18 y/o, diabetes based on ICD-9 codes or NDC codes for diabetes specific medications, and continuous eligibility in 2008. Exclusion criteria were a nursing home stay or no claims in 2008. DCs were identified based on AHRQ diabetes prevention quality indicators for shortterm complications, uncontrolled diabetes, long-term complications and amputations. Each individual was placed in one of four groups based on whether continuously enrolled in Fee for Service (FFS), Care Management (CM), Managed care (MC), or whether switches between subprograms occurred in 2008. Persons enrolled in CM entered through disability determination, while other groups had no known disability indication. Logistic regression assessed association between Medicaid subprogram and DC adjusting for age, gender, ethnicity, marital status, diabetes type, mental illness, hypertension, coronary artery disease, foot specific conditions and Charlson comorbidity index. RESULTS: A sample of 47,443 persons, with mean age of 53 years, 68% female and, 77% white was identified. Overall, 1,514 hospitalizations for DC (95% C.I., 1439 -1592) with a rate of 31.9 per 1000 individuals with diabetes was found. Although no significant difference was seen between CM or MC as compared to FFS, DCs were more likely in individuals who switched subprograms than those in FFS (Odds ratio = 1.6, 95% C.I.: = 1.4 -1.9, p≤0.001). CONCLUSIONS: Transitions between Medicaid subprograms was associated with greater likelihood of diabetes complication hospitalization. CM may reduce adverse outcomes for those persons with medical disability. Continuity of care may be essential.
PDB73 QUALITY OF CARE FOR DIABETICS IN KARACHI PAKISTAN
Khowaja S 1 , Khowaja LA 2 1 Aga Khan University, Karachi, Sindh, Pakistan, 2 Aga Khan University, Karachi, Pakistan BACKGROUND AND OBJECTIVES: Diabetes is a chronic, potentially disabling and often fatal disease. The International Diabetes Federation estimates that more than 245 million people around the world are living with diabetes. Around 3.2 million deaths are attributable to complication of diabetes every year; six deaths every minute. Pakistan is in the top ten countries in the number of sufferers from diabetes. This disease requires continuing proper medical care and patient selfmanagement education to prevent complications Current study aims to observe the current standard in the management of diabetic at a private tertiary care hospital in Karachi, Pakistan. METHODS: A retrospective health record review was done at a private tertiary care hospital at Karachi, Pakistan. Health records for all the persons with diabetes, who visited general physician or family physician during the months of April and May 2007, were included in this study. Two indicators including foot examination and advice for HbA1C diagnostic test for this cross sectional survey were identified. Data were analyzed using descriptive statistics. RESULTS: Total 350 health records were reviewed and of these, 40% were males and 60 females. Majority of the diabetics (80%) were over the age of 50 years. We found that only 40% of the patients were physically checked for foot examination and advised for HbA1C lab investigation by their general physician or family physician. About 44% were not either checked for foot examination or advised for HbA1C. CONCLUSIONS: Diabetes is a devastating chronic disease and can result in death very early if not managed properly. Current study suggest that adherence to the current screening guidelines was inadequate in this practice setting. Adherence to current diabetes management guidelines and diabetes care quality improvement initiatives can result in significant improvements in the provision and documentation of diabetes care. Metformin is the recommended initial therapy, but only 61% of patients were prescribed it as their initial therapy. The remaining patients began on a sulfonylurea (23%) or a thiazolidinedione (15%). 62% of patients who started on metformin did not add other drugs during the study, as compared to 48% of patients who started therapy on an SFU and 43% of patients who started therapy on a TZD. 1% of patients who started on metformin added/switched to basal insulin as their second drug, mean time to add/switch was 547 days. 3% of patients who started on an SFU added/switched to basal insulin as their second drug, mean time to switch was 541 days. CONCLUSIONS: Nearly 40% of type 2 diabetes patients did not initiate therapy in line with published guidelines. Patients who initiated therapy on metformin had the highest rate of remaining on monotherapy. Patients who initiated therapy with metformin also had a lower rate of switching to/adding basal insulin as their second drug than patients who initiated therapy on an SFU.
PDB74 TREATMENT OF TYPE 2 DIABETES VS. CLINICAL GUIDELINES
